Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 20, Issue 11, Pages 1785-1790Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2014.07.010
Keywords
Acute myeloid leukemia; Donor lymphocyte infusion; Complete remission
Categories
Funding
- Ministry of Health, Labour, and Welfare of Japan
- Ministry of Education, Culture, Sports and Technology of Japan
- Ministry of Health, Labour, and Welfare of Japan [H23-010]
- Grants-in-Aid for Scientific Research [24591418] Funding Source: KAKEN
Ask authors/readers for more resources
Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain, especially in the Asian population, a nationwide registry study was retrospectively performed by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation to identify the factors affecting the patient survival after DLI. Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1 year, 2 years, and 5 years were 32% +/- 4%, 17% +/- 3%, and 7% +/- 3%, respectively. Complete remission (CR) at the time of DLL which was obtained in 8% of the patients, was the strongest predictive factor for survival after DLL Therefore, long-term survival after DLI was achieved almost exclusively in patients who successfully achieved a CR before DLI, indicating the limited efficacy of DLI in a minority of patients. (C) 2014 American Society for Blood and Marrow Transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available